Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Parkinson disease: deep cerebral stimulation].

P Krack1

  • 1Département des Neurosciences Cliniques et Biologiques, Centre Hospitalier Universitaire, INSERM U 318, Université Joseph-Fourier, Grenoble, France.

Revue Neurologique
|April 15, 2003
PubMed
Summary

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective for Parkinson's disease (PD) motor symptoms and dyskinesias. STN DBS allows for reduced medication and is a cost-effective target compared to the internal pallidum (GPi).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital speech biomarkers can measure acute effects of levodopa in Parkinson's disease.

NPJ Parkinson's disease·2025
Same author

Improvement of apathy in early Parkinson's disease.

NPJ Parkinson's disease·2025
Same author

Psychiatric and cognitive symptoms of Parkinson's disease: A life's tale.

Revue neurologique·2024
Same author

Late adult-onset Niemann Pick type C (NPC): An "atypical" typical presentation at the age of 62.

Parkinsonism & related disorders·2023
Same author

A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD.

NPJ Parkinson's disease·2020
Same author

Programming parameters of subthalamic deep brain stimulators in Parkinson's disease from a controlled trial.

Parkinsonism & related disorders·2019

Area of Science:

  • Neurosurgery
  • Neurology
  • Biomedical Engineering

Context:

  • Parkinson's disease (PD) presents a significant challenge, with motor fluctuations and levodopa-induced dyskinesias impacting patient quality of life.
  • Deep brain stimulation (DBS) has emerged as a crucial therapeutic option for managing advanced PD symptoms.
  • The subthalamic nucleus (STN) and internal pallidum (GPi) are primary targets for DBS in PD, each with distinct characteristics and outcomes.

Purpose:

  • To compare the efficacy and cost-effectiveness of subthalamic nucleus (STN) DBS versus internal pallidum (GPi) DBS for Parkinson's disease.
  • To evaluate the impact of STN DBS on the parkinsonian triad (tremor, rigidity, bradykinesia) and levodopa-induced dyskinesias.
  • To establish patient selection guidelines for STN DBS based on preoperative levodopa response and clinical characteristics.

Related Experiment Videos

Summary:

  • STN DBS and GPi DBS demonstrate similar efficacy in treating the parkinsonian triad and dyskinesias, with STN DBS showing a slightly superior anti-akinetic effect.
  • STN DBS facilitates a significant reduction in dopaminergic medication (over 50%) and has a lower current drain, making it a more cost-effective target.
  • STN DBS is comparable to ventral intermediate nucleus (Vim) thalamic stimulation for PD tremor but offers additional benefits for akinesia and dyskinesias, establishing it as a preferred target.

Impact:

  • STN DBS has become the primary target for bilateral DBS in PD, supported by its efficacy, medication reduction potential, and cost-effectiveness.
  • Preoperative levodopa response strongly correlates with postoperative outcomes, enabling precise patient selection based on age (<70), absence of dementia, and severe motor fluctuations or dyskinesias.
  • Careful patient selection, surgical precision, and postoperative follow-up are critical for successful STN DBS outcomes, with severe complications being rare (approx. 1% per side).